Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses
Genre
Journal ArticleDate
2013-09-06Author
Yi, GLapelosa, M
Bradley, R
Mariano, TM
Dietz, DE
Hughes, S
Wrin, T
Petropoulos, C
Gallicchio, E
Levy, RM
Arnold, E
Arnold, GF
Subject
AIDS VaccinesAmino Acid Sequence
Animals
Antibodies, Neutralizing
Antibodies, Viral
Epitopes
Guinea Pigs
HIV Envelope Protein gp41
HIV Infections
HIV-1
HeLa Cells
Humans
Male
Molecular Sequence Data
Peptide Fragments
Peptide Library
Rhinovirus
Permanent link to this record
http://hdl.handle.net/20.500.12613/5373
Metadata
Show full item recordDOI
10.1371/journal.pone.0072205Abstract
Background:The development of an effective AIDS vaccine has been a formidable task, but remains a critical necessity. The well conserved membrane-proximal external region (MPER) of the HIV-1 gp41 glycoprotein is one of the crucial targets for AIDS vaccine development, as it has the necessary attribute of being able to elicit antibodies capable of neutralizing diverse isolates of HIV.Methodology/Principle Findings:Guided by X-ray crystallography, molecular modeling, combinatorial chemistry, and powerful selection techniques, we designed and produced six combinatorial libraries of chimeric human rhinoviruses (HRV) displaying the MPER epitopes corresponding to mAbs 2F5, 4E10, and/or Z13e1, connected to an immunogenic surface loop of HRV via linkers of varying lengths and sequences. Not all libraries led to viable chimeric viruses with the desired sequences, but the combinatorial approach allowed us to examine large numbers of MPER-displaying chimeras. Among the chimeras were five that elicited antibodies capable of significantly neutralizing HIV-1 pseudoviruses from at least three subtypes, in one case leading to neutralization of 10 pseudoviruses from all six subtypes tested.Conclusions:Optimization of these chimeras or closely related chimeras could conceivably lead to useful components of an effective AIDS vaccine. While the MPER of HIV may not be immunodominant in natural infection by HIV-1, its presence in a vaccine cocktail could provide critical breadth of protection. © 2013 Yi et al.Citation to related work
Public Library of Science (PLoS)Has part
PLoS ONEADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/5355